Latest news with #ACCG-2671
Yahoo
24-06-2025
- Business
- Yahoo
Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5, setting a price target of $79.00. The analyst reasoned that Structure Therapeutics Inc. (NASDAQ:GPCR) is poised to experience a catalyst-rich H2 2025 as its clinical trials are expected to undergo significant developments. Management expects two Phase 2b readouts in Q4, along with the initiation of the amylin first-in-human study by the end of the year. A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses. According to Song, these milestones are critical as they can determine the safety and efficacy of the compounds, especially the '1290 compound, with the potential to differentiate from competitors. Structure Therapeutics Inc. (NASDAQ:GPCR) is also exploring strategic partnerships for commercialization and ensuring manufacturing readiness as part of strategic preparations for Phase 3 trials. The analyst considers it well-positioned to capitalize on emerging opportunities and advance its clinical programs, supported by a cash runway extending to 2027. Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops novel oral therapeutics for the treatment of a range of chronic diseases with unmet medical needs. The company's pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
14-04-2025
- Business
- Yahoo
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer's latest product announcement. Early this morning, Pfizer announced it will discontinue development of its danuglipron (PF-06882961) once-a-day oral GLP-1 weight loss pill. Shares of companies will injectable GLP-1 drugs already on the market -- Eli Lilly and Novo Nordisk -- gained 2% and 2.7%, respectively, through 10:30 a.m. ET. Viking Therapeutics, which does not yet have a GLP-1 drug on the market (but like Pfizer, was racing to put one there) surged most of all, gaining 9.9% on the prospect that now Viking, and not Pfizer, may end up being the third major player in this weight loss drug market. In its press release this morning, Pfizer explained that while danuglipron exhibited the "potential to deliver a competitive efficacy and tolerability profile" to existing GLP-1 drugs, "a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron" (emphasis added). This was a strong hint that it was the drug at fault for the negative effect, and it convinced Pfizer to terminate further development. Pfizer expressed disappointment at the need to discontinue the development of danuglipron, but insisted the company remains "committed to evaluating and advancing promising programs," including in the weight loss market. But for now at least, it's no longer anywhere near the front of the pack in this race. (Pfizer stock was down 1.2% in the same time frame, by the way). The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues they've been raking in from the GLP-1 market, which helped lift Lilly past $45 billion in total revenue last year, and pushed Novo past $44 billion. Adding to Lilly's good news, investment bank Guggenheim this morning lowered its price target on the stock, but reiterated its buy rating. As the analyst explained, Lilly has a near-term catalyst that could drive the stock higher: Q1 earnings come out on May 1. And Guggenheim says that analyst forecasts for the company to earn $4.2 billion on just $12.8 billion in revenue (according to data from S&P Global Market Intelligence) look "comfortably achievable." Separately, investment bank JPMorgan commented this morning that Pfizer's discontinuation of danuglipron is "mostly a positive" for Viking Therapeutics and its VK2735 GLP-1 weight loss drug currently under development, making the company an "even more attractive partnership candidate" for a larger pharmaceutical company to team up with. JPMorgan also urged investors to take a closer look at Structure Therapeutics (NASDAQ: GPCR) and its own ACCG-2671 GLP-1 weight loss drug (another stock that was up today), which JPMorgan says is now in line to become the second small molecule oral to enter the market. Granted, like Viking, Structure is not yet a profitable company. But at a $1 billion market cap, it's less than half the cost of Viking stock -- and apparently closer to market as well! For investors looking for surer bets in the GLP-1 market, they should probably stick with Novo Nordisk or Lilly. Both stocks are solidly profitable, with Lilly posting the faster growth rate, but Novo Nordisk -- selling for less than 20 times trailing earnings -- looks significantly cheaper than Lilly at a P/E ratio of more than 62. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $495,226!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $679,900!* Now, it's worth noting Stock Advisor's total average return is 796% — a market-crushing outperformance compared to 155% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase and Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today was originally published by The Motley Fool Sign in to access your portfolio
